Oramed Pharmaceuticals Inc. (ORMP)
| Market Cap | 147.44M |
| Revenue (ttm) | 2.71M |
| Net Income (ttm) | -14.54M |
| Shares Out | 23.75M |
| EPS (ttm) | -0.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $5.53 |
| Previous Close | $4.58 |
| Change ($) | 0.95 |
| Change (%) | 20.74% |
| Day's Open | 4.63 |
| Day's Range | 4.60 - 5.70 |
| Day's Volume | 1,703,428 |
| 52-Week Range | 2.48 - 5.70 |
NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral dru...
NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug...
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral dru...
NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug...
NEW YORK, Nov, 24, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delive...
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delive...
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral dru...
Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA
NEW YORK, Oct. 16, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral dru...
NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral dr...
NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc.
NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc.
Pharmaceutical companies have poured millions—maybe billions—of dollars into research aimed at finding a way to deliver insulin to patients by mouth.
NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral dru...
About ORMP
Oramed Pharmaceuticals engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight... [Read more...]
| Industry Biotechnology | Founded 2002 |
| CEO Nadav Kidron | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol ORMP |
Financial Performance
In 2020, ORMP's revenue was $2.71 million, an increase of 0.26% compared to the previous year's $2.70 million. Losses were -$11.51 million, -19.81% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for ORMP stock is "Strong Buy." The 12-month stock price forecast is 12.60, which is an increase of 127.85% from the latest price.